Table 1

Summary of salient clinical features of the cohort

Case NoB wt (SDS)Age seenHt (SDS)Wt (SDS)OFC (SDS)“Classical”MildAsymmetry
11-150 −6.205.73−4.09−5.74−1.03+Y
2−5.1117.81−3.39−1.80−1.38+
3−4.908.63−4.38−7.40−7.34+
41-150 −4.8934.25−3.73−2.65−3.31+Y
51-150 −4.8310.74−4.72−6.93−1.38+
61-150 −4.654.34−3.68−4.87−2.45+Y
71-150 −4.6210.20−3.79−3.97−0.23+Y
81-150 −4.2720.27−3.47−1.57−1.57+
9−4.0035.06−1.87  N/A−3.31+Y
10−3.8511.06 1.21 0.51−1.43+Y
11−3.7910.77−2.60−4.54−1.95+Y
12−3.350.95  N/A−4.63−1.20+Y
13−3.320.84−5.25−7.93−2.75+
141-150 −3.1811.04−1.08−0.52 0.13+Y
151-150 −3.162.42−5.58−5.65−1.83+Y
16−3.0927.31−3.76−2.40−2.51+Y
17−3.0511.04−2.35−4.57−3.47+
181-150 −2.9412.60−0.20−0.55 0.58+
191-150 −2.7312.65 0.31 0.35−0.46+Y
201-150 −2.597.28−2.17−3.04−1.07+
21−2.5910.20−1.93−2.22−2.60+
22−2.532.01−5.37−6.29−4.61+
231-150 −2.523.26−2.97−4.12−1.08+Y
241-150 −2.149.00−1.72−1.49 0.62+
25−2.143.85−2.10  N/A−3.31+Y
26−1.714.93−3.69−5.01−1.00+
27−1.633.20−2.63−2.17−0.46+Y
28−1.5921.70−3.59−1.73−0.47+Y
29−1.510.90−3.59−3.93−0.77+
301-150 −1.366.79−3.93−2.17−1.34+
31−0.8913.57−2.32−2.17−1.34+Y
321-150 −4.6210.75−1.06−1.78−2.94+
33−4.1419.98−2.63−5.12−1.86+
34−4.086.46−3.16−4.61−2.88+
35−3.954.13−4.16−4.98−2.75+
361-150 −3.869.30 0.132−1.06−1.97+
37−3.696.64−2.15−0.36 0.03+
381-150 −3.1811.85−0.95−0.54−1.55+
391-150 −2.7214.71−0.72−1.56−1.89+
40−2.546.43−2.15−1.95−2.95+
411-150 −2.494.34−2.58−2.91−0.57+
42−2.482.88−4.84−3.81−2.10+
431-150 −1.897.94−2.71−3.08−2.77+
44−1.6520.32−3.68−0.15−1.00+
45−1.554.57−0.91−0.95−0.71+
461-150 −1.5311.73−1.53−1.58−2.17+
47−1.425.63−2.29−3.86−2.02+
48−1.279.11−2.48−2.38−0.47+
49−0.915.09−2.45−2.91−1.19+
501-150 0.2311.78−1.37−1.21 0.14+

  • ↵1-150 Denotes treatment at some stage with growth hormone.